Company Description
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.
The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits.
It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment.
In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation.
The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
| Country | United States |
| Founded | 1991 |
| IPO Date | Aug 4, 2000 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 9,707 |
| CEO | Frank Laukien |
Contact Details
Address: 40 Manning Road Billerica, Massachusetts 01821 United States | |
| Phone | 978 663 3660 |
| Website | bruker.com |
Stock Details
| Ticker Symbol | BRKR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001109354 |
| CUSIP Number | 116794108 |
| ISIN Number | US1167941087 |
| Employer ID | 04-3110160 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Burkhard Prause Ph.D. | President and Chief Executive Officer of Bruker Energy and Supercon Technologies, Inc. |
| Dr. Frank H. Laukien Ph.D. | Chairman, Chief Executive Officer and President |
| Dr. Mark R. Munch Ph.D. | Corporate Executive Vice President and President of Bruker Nano Group and Corporate |
| Juergen Srega | President of Bruker CALID Group and Bruker Daltonics Division |
| Dr. Falko Busse Ph.D. | President of Bruker BioSpin Group |
| Justin Joseph Ward | Senior Director of Investor Relations and Corporate Development |
| J. Brent Alldredge J.D. | General Counsel and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 5, 2024 | 8-K | Current Report |
| Aug 15, 2024 | 144 | Filing |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Aug 7, 2024 | 8-K | Current Report |
| Aug 6, 2024 | 8-K | Current Report |